161 related articles for article (PubMed ID: 17398203)
1. The things to come of SHAPE: cost and effectiveness of cardiovascular prevention.
Diamond GA; Kaul S
Am J Cardiol; 2007 Apr; 99(7):1013-5. PubMed ID: 17398203
[TBL] [Abstract][Full Text] [Related]
2. Cost and effectiveness of cardiovascular prevention.
Boyar A
Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
[No Abstract] [Full Text] [Related]
3. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
Naghavi M; Falk E; Hecht HS; Jamieson MJ; Kaul S; Berman D; Fayad Z; Budoff MJ; Rumberger J; Naqvi TZ; Shaw LJ; Faergeman O; Cohn J; Bahr R; Koenig W; Demirovic J; Arking D; Herrera VL; Badimon J; Goldstein JA; Rudy Y; Airaksinen J; Schwartz RS; Riley WA; Mendes RA; Douglas P; Shah PK;
Am J Cardiol; 2006 Jul; 98(2A):2H-15H. PubMed ID: 16843744
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.
Reynolds TM
J Tissue Viability; 2008 Nov; 17(4):115-20. PubMed ID: 19061825
[TBL] [Abstract][Full Text] [Related]
5. [Polish forum for prevention guidelines on cardiovascular risk assessment].
Podolec P; Kopeć G; Pajak A; Undas A; Kozek E; Tykarski A; Naruszewicz M; Stańczyk J; Opala G; Godycki-Cwirko M; Rynkiewicz A; Torbicki A; Musiał J
Kardiol Pol; 2007 Jan; 65(1):100-4. PubMed ID: 17295170
[No Abstract] [Full Text] [Related]
6. Prevention and screening. Part II: Critical appraisal of articles on screening.
Soares I; Carneiro AV
Rev Port Cardiol; 2003 Jan; 22(1):117-30. PubMed ID: 12712815
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mass and targeted screening strategies for cardiovascular risk: simulation of the effectiveness, cost-effectiveness and coverage using a cross-sectional survey of 3921 people.
Lawson KD; Fenwick EA; Pell AC; Pell JP
Heart; 2010 Feb; 96(3):208-12. PubMed ID: 19737737
[TBL] [Abstract][Full Text] [Related]
9. Preventive Cardiology: the SHAPE of the future. A Synopsis from the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
Naghavi M
Herz; 2007 Aug; 32(5):356-61. PubMed ID: 17687524
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN.
Finkelstein EA; Wittenborn JS; Farris RP
J Womens Health (Larchmt); 2004 Jun; 13(5):625-33. PubMed ID: 15257854
[TBL] [Abstract][Full Text] [Related]
11. The use of cardiovascular risk factor information in practice databases: making the best of patient data.
Marshall T
Br J Gen Pract; 2006 Aug; 56(529):600-5. PubMed ID: 16882378
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
13. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease.
Liew D; Lim SS; Bertram M; McNeil JJ; Vos T
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):515-22. PubMed ID: 16874139
[TBL] [Abstract][Full Text] [Related]
14. Progress in prevention: should we screen for risk factors or disease? A current debate in the prevention of cardiovascular events.
Dennison CR; Hughes S
J Cardiovasc Nurs; 2009; 24(1):18-20. PubMed ID: 19114796
[No Abstract] [Full Text] [Related]
15. The first SHAPE (Screening for Heart Attack Prevention and Education) guideline.
Naghavi M; Falk E; Hecht HS; Shah PK;
Crit Pathw Cardiol; 2006 Dec; 5(4):187-90. PubMed ID: 18340236
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of prevention: opportunities for public health policy in the Netherlands].
van den Berg M; de Wit GA; Vijgen SM; Busch MC; Schuit AJ
Ned Tijdschr Geneeskd; 2008 Jun; 152(23):1329-34. PubMed ID: 18661860
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease prevention tailored for women.
Engberding N; Wenger NK
Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1123-34. PubMed ID: 18793115
[TBL] [Abstract][Full Text] [Related]
18. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Inadomi JM
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
[TBL] [Abstract][Full Text] [Related]
19. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
20. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
Lamotte M; Annemans L; Kawalec P; Zoellners Y
Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
